Fundraising Fox

Variant Bio

New York, US · Founded 2018 · Delaware corporation · 5 known investors

variantbio.com

Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.

AI & Machine LearningBiotechDigital Health

Founders & leadership

Variant Bio was founded in 2018 by Kaja Wasik, Andrew Farnum, and Stephane Castel.

KWKaja Wasik
Kaja WasikCo-founder
AFAndrew Farnum
Andrew FarnumChief Executive Officer
SCStephane Castel
Stephane CastelinCo-Founder, Chief Scientific & Technology Officer
CB
Craig BassonChief Medical Officer, President of R&D
HVHolly Vance
Holly VanceChief Operating Officer

Board

JS
Julie SunderlandBoard director
JWJosh Wolfe
Josh Wolfein𝕏Board directorPartner and Co-Founder at Lux Capital
BMBob More
Bob More𝕏Board directorManaging Director at Alta Partners

Investors · 5

Reported raises · per SEC filings

Form D private placements

$127.7M disclosed across 3 of 4 rounds · 2019–2025

$105MraisedNov 2021 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stuart NagaeDirector
  • Bob MoreDirector
  • Andrew FarnumExecutive Officer, Director
  • Elena VibochDirector
  • Josh WolfeDirector
  • Stephane CastelExecutive Officer, Director
  • Julie SunderlandDirector
Offering amount
$105M
Amount sold
$105M
First sale
Oct 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$6.1MraisedAug 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Julie SunderlandDirector
  • Josh WolfeDirector
  • Bob MoreDirector
  • Kaja WasikExecutive Officer, Director
  • Andrew FarnumExecutive Officer, Director
Offering amount
$6.7M
Amount sold
$6.1M
First sale
Jul 2020
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$16.6MraisedOct 2019 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kaja WasikDirector
  • Akhila KosarajuExecutive Officer, Director
  • Adam GoulburnDirector
  • Josh WolfeExecutive Officer, Director
Offering amount
$31.5M
Amount sold
$16.6M
First sale
Sep 2019
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

Companies competing with Variant Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Variant Bio do?
Variant Bio is a therapeutics company that uses human genomics to guide drug development, drawing on expertise across genetics, molecular biology, therapeutics, anthropology, and ethics.
Who founded Variant Bio?
Variant Bio was founded by Kaja Wasik, Andrew Farnum, Stephane Castel in 2018.
Who are Variant Bio's investors?
Variant Bio's investors include Alta Partners, General Catalyst, Lux Capital, SoftBank Vision Fund, Dimension Capital.
How much funding has Variant Bio raised?
Variant Bio has disclosed $127.7M raised across 3 of its 4 known rounds.
Where is Variant Bio headquartered?
Variant Bio is headquartered in New York, US.